Tranche 2 voting, page-8

@RobP111

Was the announcement of 10 Feb 25 not helpful? Below is a copy and paste from that announcement.

Use of Proceeds

The use of proceeds from this financing will provide Alterity a strong balance sheet to fund
ongoing clinical development programs for ATH434, including planned advancements in MSA,
continuing discovery and research efforts in neurodegenerative diseases, including Parkinson’s
Disease, and general working capital.
At the end of January, the company released positive topline results from its ATH434-201 Phase
2 clinical trial of ATH434. The data demonstrated a clinically meaningful benefit at both ATH434
doses studied and the trial achieved statistical significance at the 50 mg dose with 48% slowing
of clinical progression on the Unified MSA Rating Scale (UMSARS), a functional rating scale that
assesses disability on activities of daily living affected in MSA. In addition, ATH434 demonstrated
a favorable safety profile and key MRI biomarker data showed iron stabilization in MSA affected
brain regions. Based on the strength of these Phase 2 data, the company plans to engage with
the FDA to discuss the path forward for accelerating the development of ATH434.